Eisai Co., Ltd. and Biogen, Inc. remain at least a few months ahead of Eli Lilly and Company in the race to win accelerated approval and rapidly bring a second amyloid-targeting antibody to market in the US. Eisai and Biogen announced on 5 July that the Food and Drug Administration accepted their biologics license application (BLA) for lecanemab and granted priority review, setting a 6 January action date for the early Alzheimer’s disease therapy.
If approved, lecanemab (BAN2401) would not be the first anti-amyloid antibody that the partners have brought to market with an...






